ORIGINAL RESEARCH PAPER
Volume - 14 | Issue - 09 | September - 2025 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH

ANALYSING THE INCIDENCE OF HYPONATREMIA IN HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION

General Medicine

Dr. C. Aravind HOD, Department Of General Medicine, Sri Lakshmi Narayana Institute of Medical Sciences, Pondichery, India.

Dr. Sakhamuri Krishna Rohit* Post Graduate, General Medicine, Sri Lakshmi Narayana Institute of Medical Sciences, Pondichery, India *Corresponding Author

ABSTRACT

The frequency of hyponatremia in individuals with heart failure with reduced ejection fraction (HFrEF), providing insight into an important area of therapeutic care. Low blood sodium levels, or hyponatremia, are linked to higher morbidity and mortality and are known to be a prevalent comorbidity in heart failure. Study investigates the incidence, risk factors, clinical consequences, and treatment approaches for hyponatremia in patients with HFrEF by means of a methodical review of the body of current research. Numerous investigations have shown that a significant segment of this patient group suffers from hyponatremia, which has an inverse relationship between its occurrence and ejection fraction. Study examines the complex aetiology of hyponatremia in HFrEF, which includes renal failure and neurohormonal activation. Hyponatremia has serious clinical ramifications that negatively impact prognosis, symptom severity, and quality of life. We explore the relationship between hyponatremia and important outcomes, such death and rehospitalization, and stress the need of early detection and individualised treatment. For physicians and researchers seeking a comprehensive strategy to treating hyponatremia in HFrEF, this review offers insights into novel and existing treatment options. Ultimately, the analysis may work towards better patient treatment and outcomes in the setting of heart failure with a lower ejection fraction by deepening our knowledge of this intricate interaction.

KEYWORDS

Hyponatremia, heart failure, reduced ejection fraction, prevalence, risk factors, clinical implications, therapeutic strategies

1. INTRODUCTION

Heart failure with reduced ejection fraction (HFrEF), which is characterised by a diminished heart's capacity to pump blood adequately, continues to be a major clinical concern on a global scale [1]. Hyponatremia, a disorder characterised by low blood sodium levels, is one of the many problems associated with HFrEF that is receiving more and more attention. The context for a thorough examination of the prevalence and consequences of hyponatremia in HFrEF patients is established by this introduction. Figure 1 provides a graphical representation of the categories and percentage values of hyponatremia in patients with heart failure who have a lower ejection fraction.



Figure 1. Hyponatremia in Heart Failure Patients with Reduced Ejection Fraction - Categories and Percentage Values

The frequency of hyponatremia in HFrEF emphasises both its clinical importance and its link to adverse outcomes, such as elevated hospitalisation and death rates. Therefore, it is critical for both academics and healthcare professionals to comprehend the complex terrain of hyponatremia in this setting [2]. Examining the prevalence, contributing variables, and clinical implications of hyponatremia in HFrEF, along with a look at new treatment approaches, are the objectives of this study. This study advances the overall objective of bettering patient treatment and outcomes for those suffering from this difficult cardiac disease by navigating the complex interactions between hyponatremia and HFrEF.

2. Hyponatremia In Heart Failure

A complicated clinical picture is presented by hyponatremia in heart failure. This illness is a common comorbidity in people with heart failure and is characterised by unusually low blood salt levels. It results from a series of renal dysregulations and neurohormonal imbalances, which are often made worse by the use of diuretics. In addition to lowering a patient's quality of life, hyponatremia increases hospital admissions and fatality rates. Its importance in heart failure with reduced ejection fraction (HFrEF) is highlighted by the fact that its prevalence is negatively associated with ejection fraction [3]. It is essential to comprehend the complex aetiology, clinical consequences, and treatment approaches for hyponatremia in order to provide HFrEF patients with complete care. This summary lays the groundwork for a more thorough investigation by offering a look into the complex link between hyponatremia and heart failure. The severity of hyponatremia and the various treatment modalities for individuals with heart failure are listed in Table 1.

Table 1. Hyponatremia Severity And Treatment Approaches In Heart Failure Patients

Severity of Hyponatremia	Treatment Approach
Mild	Fluid restriction
Moderate	Diuretic adjustment
Severe	Intravenous saline infusion
Mild	Medication adjustment
Moderate	Combination therapy

2.1 Classification And Properties Of Hyponatremia In Heart Failure

An electrolyte imbalance known as hyponatremia is characterised by a low serum sodium content in the blood, usually less than 135 milliequivalents per litre (mEq/L). Based on severity, it may be further divided into three categories: mild (130-134 mEq/L), moderate (125-129 mEq/L), and severe (<125 mEq/L) [4]. The relevant treatment techniques and the level of clinical urgency may be determined with the use of this categorization. Additionally, based on the patient's total body fluid state, hyponatremia may be classified as hypovolemic, euvolemic, or hypervolemic. To properly diagnose and treat hyponatremia in a variety of clinical settings, such as heart failure with a decreased ejection fraction, it is essential to comprehend these categories.

2.2 Pathophysiology

Heart failure with decreased ejection fraction has a complex aetiology of hyponatremia. Reduced cardiac output caused by HFrEF triggers neurohormonal systems such the sympathetic nervous system and the renin-angiotensin-aldosterone axis [5]. In an effort to restore cardiac output, these neurohormonal reactions cause water and salt retention, which may lower blood sodium levels. Simultaneously, hyponatremia is made worse by decreased renal function, which is frequent in HFrEF and results in the kidneys having difficulty excreting excess water. Diuretics, which are often used in the therapy of HFrEF, are one kind of medication that might cause salt loss [5]. Comprehending this complex pathophysiology is essential for customised therapy and care plans for hyponatremia in individuals with HFrEF.

2.3 Importance Of Studying Hyponatremia In Heart Failure

The extensive clinical ramifications of hyponatremia in heart failure make research on this topic crucial. Hyponatremia is a major indicator of the severity of the illness and is strongly associated with unfavourable outcomes, such as increased morbidity and death, in patients with heart failure. Its existence is linked to worsening hospitalisation rates, a worse quality of life, and worsening heart failure symptoms [6]. Furthermore, better patient outcomes and symptom alleviation are possible with appropriate hyponatremia therapy. Because of this, it is essential to understand the complex interaction between hyponatremia and heart failure in order to optimise patient care, customise treatment plans, and ultimately improve the prognosis and quality of life for those who suffer from this difficult cardiac illness.

3. Incidence And Prevalence Of Hyponatremia In HFrEF

Notable features of heart failure with decreased ejection fraction include the occurrence and prevalence of hyponatremia. HFrEF patients often have hyponatremia as a comorbidity, according to several studies. Although its frequency varies, it may impact a significant section of this population [5]. Hyponatremia and ejection fraction have been shown to have an inverse association. These results underline the therapeutic importance of treating hyponatremia in HFrEF because they demonstrate the severity of the heart failure and the necessity for all-encompassing treatment approaches to enhance patient outcomes and quality of life [7]. Comprehending the epidemiological patterns of hyponatremia in patients with HFrEF is crucial for medical professionals and researchers.

3.1 Epidemiological Trends

The prevailing epidemiological patterns of hyponatremia in heart failure with decreased ejection fraction provide important new information. Patients with HFrEF often have a hyponatremia incidence of 10% to 30%; a greater prevalence is linked to more severe heart failure [8]. Hyponatremia and ejection fraction have been shown to be inversely correlated, with lower ejection fractions being associated with a greater risk of hyponatremia. Moreover, the use of diuretics, age, and comorbidities all influence the variation in prevalence. Clinicians must be aware of these epidemiological tendencies in order to identify patients who are at-risk early and provide the best treatment possible, which will eventually affect the prognosis of those who have hyponatremia and HFrEF [8].

3.2 Factors Influencing Incidence

Several important variables impact the occurrence of hyponatremia in heart failure with decreased ejection fraction. Hyponatremia is exacerbated by neurohormonal activation, which is frequent in HFrEF and causes the retention of water and salt [9]. One of the mainstays of managing HFrEF is the use of diuretics, which exacerbates the illness by increasing salt loss. Patients with HFrEF have reduced renal function, which makes it harder for the kidneys to eliminate extra water and maintain an electrolyte balance. Furthermore, a crucial factor is the degree of heart failure as determined by the ejection fraction; a greater prevalence of hyponatremia is correlated with lower ejection fractions (Table 2). It is crucial to comprehend these complex variables in order to effectively prevent and treat hyponatremia in HFrEF patients [9].

Table 2. Factors Influencing Incidence Of Hyponatremia In HFrEF

Factor	Description
Neurohormonal Activation	Activation of systems like the renin-angiotensin-aldosterone axis and the sympathetic nervous system in HFrEF leading to sodium and water retention.
Medications and Diuretics	Use of diuretics in HFrEF management can contribute to sodium loss. Other medications affecting sodium balance can also influence incidence.
Renal Dysfunction	Impaired renal function diminishes the kidney's ability to maintain electrolyte balance, leading to sodium retention.
Severity of Heart Failure (Ejection Fraction)	Lower ejection fractions are associated with a higher incidence of hyponatremia in HFrEF.
Age and Comorbidities	Advanced age and comorbidities, such as kidney disease or liver dysfunction, can heighten the risk of hyponatremia.

3.3 Relationship With Ejection Fraction

One important component of patient management in heart failure is the correlation between hyponatremia and ejection fraction. Research continuously demonstrates that in heart failure with decreased ejection fraction (HFrEF), ejection fraction and hyponatremia are inversely correlated [10]. This suggests that the risk of having hyponatremia rises with decreasing ejection fraction, which indicates a more compromised cardiac function. Patients with HFrEF who have a lower ejection fraction are more susceptible to this electrolyte imbalance. Understanding this association is essential because it helps with risk classification, which directs appropriate therapy and interventions to enhance patient outcomes and well-being, as well as highlighting the severity of the heart failure disease [10].

4. Risk Factors For Hyponatremia In HFrEF

Heart failure with decreased ejection fraction (HFrEF) has a variety of risk factors for hyponatremia. Hyponatremia is exacerbated by neurohormonal activation, which leads to salt and water retention and increased production of aldosterone and antidiuretic hormone. Sodium loss is exacerbated by the use of diuretics, which are often used to treat fluid excess in HFrEF [11]. The kidney's capacity to eliminate extra water is hampered by impaired renal function, which is often seen in HFrEF patients. The severity of heart failure, comorbidities such as liver or renal illness, and advanced age may further increase the risk of hyponatremia. Effectively avoiding and treating hyponatremia in people with HFrEF requires an understanding of these risk factors.

4.1 Neurohormonal Activation

The development of hyponatremia in heart failure with reduced ejection fraction is largely dependent on neurohormonal activity [12]. When a heart fails, it sets off compensatory processes that cause an increase in water and salt retention. These mechanisms include the sympathetic nervous system and the renin-angiotensin-aldosterone system. The goal of this neurohormonal reaction is to increase cardiac output, but it often causes fluid overload, which lowers salt levels in the blood. Increased antidiuretic hormone (ADH) levels encourage water conservation, which exacerbates this imbalance even further [5]. Comprehending the complex relationship between neurohormonal activity in HFrEF is essential, as it illuminates the pathophysiological foundation of hyponatremia and guides therapy approaches aimed at reestablishing electrolyte equilibrium.

4.2 Renal Dysfunction

Hyponatremia in heart failure with decreased ejection fraction is mostly caused by renal impairment. Reduced glomerular filtration rate results from compromised renal perfusion caused by reduced heart function in HFrEF. The kidney's capacity to eliminate extra water and preserve electrolyte balance is hampered by this renal insufficiency, which leads to salt retention and the emergence of hyponatremia [13]. Moreover, renal salt and water retention are made worse by neurohormonal activation in HFrEF, which includes elevated production of aldosterone and antidiuretic hormone (ADH). In order to effectively monitor and treat hyponatremia in these patients, it is essential to comprehend the effects of renal dysfunction in the setting of HFrEF.

4.3 Medications And Comorbidities

Hyponatremia in heart failure with decreased ejection fraction is also influenced by medications and comorbidities. Drugs like loop diuretics, which are often used to treat HFrEF, might cause significant sodium loss by encouraging diuresis. Furthermore, hyponatremia may be made worse by other drugs that impact renal function or the salt balance. The body's capacity to maintain electrolyte balance might be further compromised by comorbidities such as renal disease, liver failure, and endocrine diseases [14]. In order to successfully avoid or manage hyponatremia in the setting of HFrEF, healthcare practitioners must take into account the whole clinical picture, modify their treatment plans, and continuously monitor their patients. This is made possible by acknowledging the effects of drugs and concomitant diseases.

5. Clinical Implications Of Hyponatremia In Heart Failure

Hyponatremia in heart failure with a lower ejection fraction has significant clinical ramifications. Hyponatremia worsens symptoms, lowers quality of life, and increases the likelihood of hospitalisation, all of which have a substantial negative influence on patients' health and prognosis. It is linked to an increased incidence of exacerbations of heart failure, which result in repeated hospitalisations. Furthermore, hyponatremia is associated with a

greater mortality risk in individuals with HFrEF. Its existence draws attention to a more complicated and severe clinical picture, requiring careful treatment techniques that address electrolyte abnormalities as well as heart failure [4,6]. Gaining an understanding of these clinical consequences is essential to improve patient treatment and, eventually, HFrEF outcomes. Table 3 outlines the clinical consequences of hyponatremia in patients who have heart failure.

Table 3. Hyponatremia's Clinical Consequences In Heart Failure

Clinical Implication	Description	Severity	Management	Prognosis
Symptom Severity and Quality of Life	Hyponatremia intensifies symptoms in heart failure, leading to increased fatigue, nausea, confusion, and muscle cramps, significantly reducing the patient's quality of life.	High	Symptomatic relief, sodium correction	Alters prognosis due to symptom severity.
Impact on Hospitalization	Hyponatremia often leads to higher hospitalization rates in heart failure patients, primarily due to worsening heart failure symptoms, requiring frequent medical care and management.	Moderate	Hospital-based management	Impacts prognosis due to recurrent admissions.
Prognosis and Mortality	Hyponatremia is a strong predictor of adverse outcomes, including higher mortality rates in heart failure, reflecting the severity of the condition and its impact on patient prognosis.	High	Focus on hyponatremia correction	Adversely affects prognosis.
Cognitive Impairment	Low sodium levels can lead to cognitive impairment, contributing to difficulties in daily functioning for heart failure patients.	Moderate	Cognitive assessments, addressing underlying causes	Affects quality of life and outcomes.
Complications	Hyponatremia may lead to various complications such as arrhythmias and an increased risk of falls, affecting overall well-being and patient outcomes.	Moderate to High	Targeted management of complications	Elevates risk and impacts prognosis.

5.1 Symptom Severity And Quality Of Life

In heart failure patients with a low ejection fraction, hyponatremia dramatically exacerbates symptoms and lowers their quality of life. Reduced serum sodium levels worsen the pain and debilitation brought on by heart failure and are linked to increased tiredness, nausea, disorientation, and cramping in the muscles [15]. These symptoms lower the quality of life for patients by limiting their physical activities and depressing their general wellbeing. Hyponatremia control is crucial for reducing these symptoms as well as for enhancing patients' general comfort and capacity for daily activities, all of which may have a significant influence on how well their HFrEF is managed and how well they feel overall.

5.2 Impact On Hospitalization

Patients with heart failure and low ejection fraction are more likely to be hospitalised when hyponatremia is present. Because of the increasing symptoms of heart failure brought on by this electrolyte imbalance, hospital hospitalisations are often necessary. Hyponatremia worsens congestion and fluid retention, which makes patients more breathless and edematous and may lead them to seek medical attention [16]. Hospitalisations are expensive and linked to a higher risk of complications and readmissions in patients with HFrEF. Understanding the connection between hospitalisations and hyponatremia is important because it highlights the need for proactive management techniques targeted at treating and preventing hyponatremia in order to lessen the strain on healthcare resources and enhance the general care provided to HFrEF patients.

5.3 Prognosis And Mortality

The prognosis and mortality of heart failure with a decreased ejection fraction are significantly impacted by hyponatremia. In patients with HFrEF, this electrolyte imbalance is predictive of worse outcomes. Research continuously demonstrates that people with hyponatremic levels are much more likely to die than those with normal sodium levels. It functions as a potent, independent predictor of a more unfavourable clinical course [10,17]. In addition to reflecting the severity of HFrEF, hyponatremia also increases morbidity and mortality, highlighting the urgent need to treat and manage this illness in order to enhance the general survival and well-being of those living with HFrEF.

6. Diagnosis And Assessment Of Hyponatremia

A thorough strategy is necessary for the identification and evaluation of hyponatremia in heart failure with diminished ejection fraction. Serum sodium levels are measured as part of the laboratory assessment process; results less than 135 mEq/L are indicative of hyponatremia. Clinical evaluation aids in the identification of possible underlying causes or contributing variables by taking into account the patient's medical history, physical examination, and symptoms [6]. In order to determine the proper course of therapy for a certain form of hyponatremia, such as hypovolemic, euvolemic, or hypervolemic, differential diagnosis is essential. In the setting of HFrEF, prompt and precise diagnosis and evaluation of hyponatremia are crucial for putting customised treatment plans into place, taking care of the underlying causes, and enhancing patient outcomes.

6.1 Laboratory Evaluation

Diagnosing and treating hyponatremia in heart failure with a decreased ejection fraction heavily relies on laboratory assessment. It is a measurement of the salt content in the serum; hyponatremia is defined as levels of less than 135 milliequivalents per litre, or mEq/L [18]. To grade the severity of the electrolyte imbalance, this quantitative measurement is essential. Further testing may also be carried out to determine the underlying causes of hyponatremia, measure the existence of other electrolyte abnormalities, and evaluate renal function, all of which will aid medical professionals in customising their treatment plans. In order to accurately diagnose and effectively treat hyponatremia in patients with HFrEF, laboratory examination is a crucial component of the clinical assessment process [18].

6.2 Clinical Assessment

The diagnosis and treatment of hyponatremia in heart failure with decreased ejection fraction depend heavily on clinical evaluation. It includes a thorough assessment of the patient's symptoms, a complete review of their medical history, and a thorough physical examination. Healthcare professionals may utilise this evaluation to determine the effect of hyponatremia on the patient's overall clinical condition as well as any underlying causes and contributing variables [19]. To determine the severity of the disease, symptoms that are frequent in hyponatremic patients such as disorientation, weariness, nausea, and cramping in the muscles—are evaluated. In addition to laboratory examination, clinical assessment offers a comprehensive perspective that directs customised treatment plans to successfully manage hyponatremia in the setting of HFrEF.

6.3 Differential Diagnosis

Characterising the kind of hyponatremia and determining its underlying causes are important steps in the differential diagnosis of hyponatremia in heart failure with diminished ejection fraction. In order to prescribe the right course of action, this difference is essential. The three main types of hyponatremia are hypervolemic, euvolemic, and hypovolemic. Fluid loss may cause hypovolemic hyponatremia, but syndrome of inappropriate antidiuretic hormone secretion (SIADH) is usually the cause of euvolemic hyponatremia [20]. Congestive heart failure is one of the disorders associated with hypervolemic hyponatremia. Since addressing the underlying cause is critical for effective care and the best possible results for patients with HFrEF and hyponatremia, accurate categorization is necessary for focused therapy.

7. Therapeutic Strategies For Managing Hyponatremia In HFrEF

Hyponatremia in heart failure with low ejection fraction requires complex management. This comprehensive approach has multiple parts: Fluid restriction reduces salt dilution, especially in euvolemic or hypervolemic hyponatremia. Second, moderate instances may benefit from judicious salt supplementation to prevent sodium excess. Third, diuretics must be dosed to limit sodium loss. Tolvaptan and other vasopressin receptor antagonists increase water excretion and serum

sodium. By treating HFrEF, beta-blockers and ACE inhibitors may indirectly treat hyponatremia. Serum sodium levels and clinical symptoms must be monitored closely for prompt changes. Finally, hyponatremia must be diagnosed and treated for underlying causes including renal failure or endocrine abnormalities. This method works best when tailored to the kind of hyponatremia. Table 4 outlines the therapeutic strategies that can be used to manage hyponatremia in HFrEF patients.

Table 4. Effective Treatment Plans For Hyponatremia In HFrEF

Strategy	Description
Fluid Restriction	Controlled reduction of daily water intake to alleviate fluid overload and sodium dilution, particularly useful in euvolemic or hypervolemic hyponatremia.
Sodium Supplementation	Adjusting dietary sodium intake or sodium-based medications in cases of mild hyponatremia, with careful monitoring to prevent sodium overload.
Diuretic Management	Modification of diuretic therapy, including dose reduction or adjusted dosing frequency to prevent excessive sodium loss.
Vasopressin Receptor Antagonists	Medications like tolvaptan, which block the effects of antidiuretic hormone (ADH), promoting increased water excretion and raising serum sodium levels.
Optimizing HFrEF Management	Enhancing heart failure treatment, including medications like beta-blockers and ACE inhibitors, to indirectly ameliorate hyponatremia by addressing the primary condition.

7.1 Sodium Supplementation

Increasing dietary salt consumption or giving sodium-based drugs is known as sodium supplementation, and it is a therapeutic approach used to treat hyponatremia, a disease characterised by low blood sodium levels. Modest hyponatremia may sometimes be controlled with dietary salt changes, although careful observation is needed to avoid sodium excess. Supplementing with sodium is very important in some clinical situations, such as sodium deficiency experienced by individuals suffering from heart failure, liver illness, or renal problems [21]. It must be used carefully however, since consuming too much salt may cause hypertension and other health issues. The exact dosage of salt supplementation is determined by the patient's specific hyponatremia, including its severity and underlying causes.

7.2 Fluid Restriction

Fluid restriction is a treatment strategy used to treat hyponatremia, a disorder marked by low blood salt levels. It involves gradually reducing daily water consumption. When there is an excess of total body fluid, such as in euvolemic or hypervolemic hyponatremia, this tactic is very helpful. Fluid restriction lessens fluid overload and, as a result, the dilution of sodium by restricting the amount of water consumed [6]. To make sure that the limitation does not cause dehydration, however, close observation is necessary, particularly in patients who have underlying heart failure or renal illness. To balance salt correction with ensuring proper hydration, proper implementation and supervision are crucial.

7.3 Pharmacological Interventions

Low blood sodium levels are the hallmark of hyponatremia, a disease for which pharmacological therapies are crucial to therapy. Tolvaptan and other vasopressin receptor antagonist medications are essential for treating this electrolyte imbalance. These medications prevent the effects of antidiuretic hormone (ADH), which controls the kidneys' ability to reabsorb water [11]. Vasopressin receptor antagonists enhance water excretion and raise blood salt levels via blocking ADH. This tailored strategy is especially helpful when salt supplementation and hydration restriction may not be possible or adequate. In individuals with hyponatremia, proper dose and monitoring are essential to achieving the optimal salt balance without side effects.

7.4 Underlying Heart Failure Management

Managing the underlying heart failure is essential to treating hyponatremia, which is defined as low blood sodium levels. Sustaining cardiac failure, particularly when there is a low ejection fraction, helps to mitigate hyponatremia indirectly. This entails making the best use of drugs such as ACE inhibitors and beta-blockers, which improve heart function and help regulate salt and fluid balance [22]. These drugs lessen the severity of fluid overload, which often contributes to hyponatremia, by better controlling heart failure. Improving patient outcomes and general well-being requires a comprehensive strategy that addresses both hyponatremia and heart failure.

8. Current Challenges And Future Directions

Optimising currently available therapy approaches while taking into account possible adverse effects and patient-specific characteristics is one of the current problems in controlling hyponatremia in heart failure with lower ejection fraction. Precise risk classification and choosing the best therapies for specific situations are further challenges [5]. The creation of innovative pharmaceuticals with enhanced safety and effectiveness profiles as well as personalised medicine strategies might be future developments in this discipline. In order to develop novel therapeutic approaches, research must also concentrate on gaining a greater knowledge of the underlying pathophysiology of hyponatremia in HFrEF. The ultimate objective is to improve the quality of life and clinical results of HFrEF patients by refining and expanding the techniques available for controlling hyponatremia.

8.1 Emerging Therapeutic Approaches

Novel pharmacological medicines that more accurately target the underlying processes are being used in emerging treatment approaches for hyponatremia in heart failure with lower ejection fraction. The possibility of non-peptide vasopressin antagonists and other cutting-edge medications to treat hyponatremia with better safety and effectiveness is still being investigated. Furthermore, personalised medicine approaches that are centred on the specific characteristics of each patient are becoming more and more popular. These approaches enable customised therapy regimens to target the particular causes of hyponatremia in HFrEF [5]. These new methods have the potential to improve patient outcomes and wellbeing.

8.2 Research Gaps And Potential Innovations

Refinement of patient risk classification and long-term effects investigation of novel therapeutics are research needs in the management of hyponatremia in heart failure with decreased ejection fraction. Innovations might take the shape of new pharmaceuticals that more successfully target the neurohormonal pathways underlying hyponatremia or sophisticated diagnostic instruments for accurate risk assessment. Additionally, investigating the combination of remote monitoring and digital health technologies may improve patient outcomes and treatment for HFrEF patients with hyponatremia.

9. CONCLUSION

An intricate and multidimensional link with important therapeutic consequences is shown by analysing hyponatremia in heart failure patients with diminished ejection fraction. A common comorbidity in HFrEF, hyponatremia is clinically significant since it is often negatively linked with ejection fraction. It is an essential part of managing patients with HFrEF because it affects the intensity of their symptoms, their quality of life, hospitalisation rates, and death. A multimodal strategy is needed to address hyponatremia in HFrEF, including sodium supplementation, fluid restriction, vasopressin receptor antagonists, diuretic control, optimising heart failure medication, and vigilant monitoring. It is critical to customise the course of therapy for each patient based on their unique kind of hyponatremia.

The current issues include precisely risk stratifying patients, choosing the best therapies for each instance, and balancing therapy to prevent consequences. Novel pharmaceuticals, personalised medicine strategies, and increased understanding of the pathophysiology of hyponatremia in HFrEF are potential future avenues. Our knowledge of hyponatremia in HFrEF and how to treat it will surely progress as we work through these advances and difficulties, which will eventually improve patient care and outcomes in this challenging clinical setting.

REFERENCES

[1] Xia J, Hui N, Tian L, Liang C, Zhang J, Liu J, et al. Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF). Biomed Pharmacother 2022;149:112894. https://doi.org/https://doi.org/10.1016/j.biopha.2022.112894.

[2] Pavlovic N V, GILOTRA NA, LEE CS, NDUMELE C, MAMMOS D, DENNISONHIMMELFARB C, et al. Fatigue in Persons With Heart Failure: A Systematic Literature Review and Meta-Synthesis Using the Biopsychosocial Model of Health. J Card Fail 2022;28:283–315. https://doi.org/https://doi.org/10.1016/j.cardfail.2021.07.005.

[3] Duran A, Tutor A, Shariati F, Sleem A, Wever-Pinzon J, Desai S, et al. Preimplant Hyponatremia Does Not Predict Adverse Outcomes in Patients With Left Ventricular Assist Devices. Curr Probl Cardiol 2023;48:101239. https://doi.org/https://doi.org/10.1016/j.cpcardiol.2022.101239.

[4] Praharaj DL, Anand AC. Clinical Implications, Evaluation, and Management of

Hyponatremia in Cirrhosis. J Clin Exp Hepatol 2022;12:575–94. https://doi.org/https://doi.org/10.1016/j.jceh.2021.09.008.
[5] Vohra M, Amir M, Osoro I, Sharma A, Kumar R. Impact of vericiguat on heart failure with reduced ejection fraction: a review. Glob Heal J 2023;7:123–9. https://doi.org/https://doi.org/10.1016/j.glohj.2023.07.004.
[6] Workeneh BT, Meena P, Christ-Crain M, Rondon-Berrios H. Hyponatremia Demystified: Integrating Physiology to Shape Clinical Practice. Adv Kidney Dis Heal 2023;30:85–101. https://doi.org/https://doi.org/10.1053/j.akdh.2022.11.004.
[7] Tamargo J, Caballero R, Delpón E. Sex-related differences in the pharmacological treatment of heart failure. Pharmacol Ther 2022;229:107891. https://doi.org/https://doi.org/10.1016/j.pharmthera.2021.107891.
[8] Ranek MJ, Berthiaume JM, Kirk JA, Lyon RC, Sheikh F, Jensen BC, et al. Chapter 5 - Pathophysiology of heart failure and an overview of therapies. In: Buja LM, Butany JBT-CP (Fifth E, editors., Academic Press; 2022, p. 149–221. https://doi.org/https://doi.org/10.1016/B978-0-12-822224-9.00025-6.
[9] Li L, Zhang Q, Yang H, Undergraduate SL. Incidence and related influencing factors of workplace violence among psychiatric nurses in China: A systematic review and Meta-analysis. Arch Psychiatr Nurs 2022;40:68–76. https://doi.org/https://doi.org/10.1016/j.apnu.2022.04.005.
[10] Talha KM, Greene SJ, Butler J, Khan MS. Frailty and Its Implications in Heart Failure with Reduced Ejection Fraction: Impact on Prognosis and Treatment. Cardiol Clin 2023;41:525–36. https://doi.org/https://doi.org/10.1016/j.ccl.2023.06.002.
[11] Tang H, Xu C, Zhang P, Luo T, Huang Y, Yang X. A profile of SGLT-2 inhibitors in hyponatremia: The evidence to date. Eur J Pharm Sci 2023;184:106415. https://doi.org/https://doi.org/10.1016/j.ejps.2023.106415.
[12] Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure. J Card Fail 2022;28:e1–167. https://doi.org/https://doi.org/10.1016/j.cardfail.2022.02.010.
[13] Kharawala A, Safiriyu I, Olayinka A, Hajra A, Seo J, Akunor H, et al. Incidence, predictors and outcomes of new onset systolic heart failure following orthotopic liver transplant: A systematic review. Transplant Rev 2023;37:100758. https://doi.org/https://doi.org/10.1016/j.trre.2023.100758.
[14] Rahhal A, Najim M, Abusweireh A, Habra M, Elgassim L, Ali MO, et al. A Comparative Study of Safety Outcomes of Sodium Glucose Cotransporter-2 Inhibitors and Loop Diuretics Among Diabetic Patients Using Real-world Data. Curr Probl Cardiol 2022;47:100995. https://doi.org/https://doi.org/10.1016/j.cpcardiol.2021.100995.
[15] Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement. J Am Coll Cardiol 2023;81:1810–34. https://doi.org/https://doi.org/10.1016/j.jacc.2023.01.049.
[16] Ducharme A, Zieroth S, Ahooja V, Anderson K, Andrade J, Boivin-Proulx L-A, et al. Canadian Cardiovascular Society-Canadian Heart Failure Society Focused Clinical Practice Update of Patients With Differing Heart Failure Phenotypes. Can J Cardiol 2023;39:1030–40. https://doi.org/https://doi.org/10.1016/j.cjca.2023.04.022.
[17] Soufi MK, Almahmoud MF, Kadri AN, Dang A, Jain RR, McFarland JR, et al. Heart Failure With Stable Mildly-reduced Ejection Fraction: Prognosis and Predictors of Outcomes. Curr Probl Cardiol 2023;48:101631. https://doi.org/https://doi.org/10.1016/j.cpcardiol.2023.101631.
[18] Fukata M. Acute Decompensated Heart Failure in Patients with Heart Failure with Reduced Ejection Fraction. Heart Fail Clin 2020;16:187–200. https://doi.org/https://doi.org/10.1016/j.hfc.2019.12.007.
[19] Gross CR, Varghese R, Zafirova Z. Perioperative Management of Novel Pharmacotherapies for Heart Failure and Pulmonary Hypertension. Anesthesiol Clin 2023. https://doi.org/https://doi.org/10.1016/j.anclin.2023.09.004.
[20] Serrano WC, Maldonado J. The Use of Physostigmine in the Diagnosis and Treatment of Anticholinergic Toxicity After Olanzapine Overdose: Literature Review and Case Report. J Acad Consult Psychiatry 2021;62:285–97. https://doi.org/https://doi.org/10.1016/j.jaclp.2020.12.013.
[21] Alves VR, Gonçalves S, Daguer H, Micke GA, Vitali L. Development of a new method for the determination of 4-hydroxyproline as a measurement of collagen content in meat products and dietary supplements by cyclodextrin-assisted electrokinetic chromatography. J Food Compos Anal 2023;122:105431. https://doi.org/https://doi.org/10.1016/j.jfca.2023.105431.
[22] Dye C, Dela Cruz M, Larsen T, Nair G, Marinescu K, Suboc T, et al. A review of the impact, pathophysiology, and management of atrial fibrillation in patients with heart failure with preserved ejection fraction. Am Hear J Plus Cardiol Res Pract 2023;33:100309. https://doi.org/https://doi.org/10.1016/j.ahjo.2023.100309.